Novo Nordisk’s Awiqli approval could change how basal insulin is used in type 2 diabetes
Novo Nordisk’s Awiqli wins FDA approval as the first once-weekly basal insulin. Read what this could change for type 2 diabetes care.
How Agilent’s PD-L1 companion diagnostic now shapes pembrolizumab access in esophageal carcinoma
FDA approves Agilent’s PD-L1 IHC 22C3 pharmDx for esophageal and GEJ carcinoma, marking the eighth companion diagnostic indication alongside pembrolizumab. Read the analysis.
Can Drug Farm turn ALPK1 inhibition into the first real disease-modifying approach for ROSAH syndrome?
Drug Farm won FDA orphan drug designation for DF-003 in ROSAH syndrome. Read what this rare disease milestone could change next.
What the NEOK002 IND milestone changes for Biocytogen, NEOK Bio, and ADC competition
NEOK002 has cleared the FDA IND stage. Read why this bispecific ADC matters for solid tumors, clinical strategy, and the next phase of ADC competition.
What the Hims & Hers Health, Inc. and Novo Nordisk collaboration reveals about the future of obesity drug commercialization
Explore how Hims & Hers and Novo Nordisk are expanding GLP-1 access and what it means for obesity care, pricing, and regulation.
Can Lunai Bioworks Inc.’s BBB delivery platform unlock scalable Alzheimer’s drug development advantages?
Can Lunai Bioworks Inc. overcome the blood brain barrier in Alzheimer’s treatment? Discover what this $20M deal changes for CNS drug development.
Can AbbVie’s Juvéderm strategy turn subtle aesthetics into the next growth engine for fillers
AbbVie is repositioning Juvéderm for the “undetectable” aesthetics era. Read what this means for injectables, clinicians, and market competition.
Denteric’s GPV381 enters Phase 2, but can a therapeutic vaccine really change periodontitis care?
Denteric’s GPV381 has entered Phase 2 in periodontitis. Read why the gingipain-targeting vaccine could test a new treatment model.
Lupin Limited moves closer to the Wakix market as pitolisant tentative approval sharpens future optionality
Lupin Limited has won tentative FDA approval for pitolisant tablets. Read why timing, exclusivity, and Wakix market dynamics matter next.
Why GC Biopharma’s BARYCELA approval in Guatemala matters beyond one Latin American market
GC Biopharma won Guatemala approval for BARYCELA. Read what this means for Latin America, vaccine supply strategy, and varicella market competition.